RGEN News and Press, Repligen Corporation From 05/01/19

Heron Therapeutics (NASDAQ: HRTX )  -24%  after FDA rejects application for pain med HTX-011. More news on: Heron Therapeutics, Inc., Nabriva Therapeutics plc, CM Seven Star Acquisition Corporation, Stocks on the move, Read more ...

WALTHAM, Mass., April 30, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced the pricing of an underwritten public offering of 2,734,375 shares of its common stock at a public offering price of $64.00 per share. In addition, Repligen Corporation has granted the und...

Quick Take Repligen Corporation ( RGEN ) announced it has agreed to acquire C Technologies for about $240 million. C Technologies manufactures fiber optic assemblies, instrumentation, as well as systems for spectroscopy applications. With the deal, RGEN is adding a fourth business segm...

WALTHAM, Mass., April 29, 2019 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of $175,000,000 in shares of its common stock. In addition, Repligen Corporation expects to grant the underwriters a 30-day option to ...

Portola Pharmaceuticals ( PTLA ) - The company announced that the European Commission granted conditional Marketing Authorization for Ondexxya (andexanet alfa) to be used in adult patients treated with the Factor Xa inhibitor apixaban or rivaroxaban when reversal of anticoagulation is needed...

Repligen ( RGEN ) is a very interesting business which I have last checked upon in the summer of 2017. The company is relatively small but is growing rapidly through both organic growth and savvy deal-making, playing a key role in the emergence of so-called biologics-based drugs. I applau...

Gainers:  Aratana Therapeutics (NASDAQ: PETX ) +37% . India Globalization Capital (NYSEMKT: IGC ) +30% . Regional Health Properties (NYSEMKT: RHE ) +32% . Helen of Troy (NASDAQ: HELE ) +21% . Sonic Automotive (NYSE: SAH ) +15% . Repligen (NASDAQ: RGEN ) +15% . IMV (NASDAQ: IMV )...

Repligen (NASDAQ: RGEN ) has entered into a definitive agreement to acquire privately-held C Technologies, Inc. for ~$240M, comprised of $192M in cash and $48M in common stock. More news on: Repligen Corporation, , Merger & acquisition news, Read more ...

Proposed acquisition establishes a key franchise for Repligen in the rapidly growing Process Analytics segment of bioprocessing Adds a market leader in protein concentration measurement with proprietary and differentiated spectroscopy technology Complements and advances our systems...

Repligen Corporation (RGEN) Q4 2018 Earnings Conference Call February 21, 2019 8:30 AM ET Company Participants Sondra Newman – Senior Director-Investor Relations Tony Hunt – President and Chief Executive Officer Jon Snodgres – Chief Financial Officer Confe...